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Introduction: Because of ongoing controversy, renal and vital outcomes are compared between systemically
administered unfractionated heparin and regional anticoagulation with citrate-buffered replacement solution in
predilution mode, during continuous venovenous hemofiltration (CVVH) in critically ill patients with acute kidney
injury (AKI).
Methods: In this multi-center randomized controlled trial, patients admitted to the intensive care unit requiring
CVVH and meeting inclusion criteria, were randomly assigned to citrate or heparin. Primary endpoints were mortality
and renal outcome in intention-to-treat analysis. Secondary endpoints were safety and efficacy. Safety was defined as
absence of any adverse event necessitating discontinuation of the assigned anticoagulant. For efficacy, among other
parameters, survival times of the first hemofilter were studied.
Results: Of the 139 patients enrolled, 66 were randomized to citrate and 73 to heparin. Mortality rates at 28 and 90 days
did not differ between groups: 22/66 (33%) of citrate-treated patients died versus 25/72 (35%) of heparin-treated patients
at 28 days, and 27/65 (42%) of citrate-treated patients died versus 29/69 (42%) of heparin-treated patients at 90 days
(P = 1.00 for both). Renal outcome, i.e. independency of renal replacement therapy 28 days after initiation of CVVH in
surviving patients, did not differ between groups: 29/43 (67%) in the citrate-treated patients versus 33/47 (70%) in
heparin-treated patients (P = 0.82). Heparin was discontinued in 24/73 (33%) of patients whereas citrate was discontinued
in 5/66 (8%) of patients (P < 0.001). Filter survival times were superior for citrate (median 46 versus 32 hours, P = 0.02), as
were the number of filters used (P = 0.002) and the off time within 72 hours (P = 0.002). The costs during the first 72 hours
of prescribed CVVH were lower in citrate-based CVVH.
Conclusions: Renal outcome and patient mortality were similar for citrate and heparin anticoagulation during CVVH in
the critically ill patient with AKI. However, citrate was superior in terms of safety, efficacy and costs.
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Despite major improvements in therapy, the mortality rate
for critically ill patients with acute kidney injury (AKI) re-
mains 50% or higher [1]. Continuous venovenous haemo-
filtration (CVVH) is commonly used as renal replacement
therapy in the ICU. The risk of clotting necessitates con-
tinuous anticoagulation for maintaining patency and func-
tion of the extracorporeal circuit and filter. Clotting and
the resultant filter down-time adversely affect azotaemic
control [2]. Excessive anticoagulation, however, may result
in bleeding complications reported to occur in 10 to 50%
of treatments [3]. Many anticoagulation methods have
been pursued including low-dose heparin, low-molecular-
weight heparin, prostanoids, mesilates and regional citrate
anticoagulation. Heparin remains a commonly used anti-
coagulant for continuous renal replacement therapy. It is
relatively easy to use and monitor and provides adequate
extracorporeal anticoagulation. However, the risk of bleed-
ing and development of heparin-induced thrombocytopenia
(HIT) are important drawbacks.
By chelating calcium, citrate acts regionally as an anti-
coagulant when administered pre-filter and thereby reduces
the risk of bleeding compared to systemic anticoagulation.
Citrate is cleared by the tricarboxylic acid pathway in the
liver, skeletal muscles and renal cortex producing bicarbon-
ate. Citrate carries the risk of hypocalcaemia when it is
insufficiently metabolized and thus accumulates. Also,
metabolic acidosis may develop when citrate is insuffi-
ciently metabolized, while metabolic alkalosis develops
when too much citrate enters the circulation and is subse-
quently metabolized. Moreover, when calcium-free replace-
ment fluids are used, calcium supplementation is required.
Citrate has been successfully adapted for use in continuous
renal replacement therapies [4-9]. Several clinical trials
comparing heparin to citrate for CVVH in critically ill pa-
tients have been published, yet most with small patient
numbers and mainly focusing on filter survival times,
with varying results [10-13]. In a recent study, low-
molecular-weight heparin was compared to regionally
administered citrate in post-dilutional CVVH. Interest-
ingly, citrate-treatment reduced mortality which could
be partly explained by less bleeding, suggesting im-
proved biocompatibility for citrate as compared to heparin-
based CVVH [14]. On the contrary, another recent trial
comparing unfractionated heparin to citrate in predilutional
CVVH did not show a survival benefit for citrate [15]. Two
meta-analyses on this topic showed no difference in mortal-
ity, however, citrate reduced the risk of bleeding and was
more efficacious in one of them [3,16].
The aim of this study was to compare regional citrate
anticoagulation to systemic anticoagulation with unfractio-
nated heparin during CVVH in a predilutional mode in
terms of patient mortality, renal outcome, safety and effi-
cacy. We hypothesized that regional citrate anticoagulationis a safe and efficient anticoagulant in critically ill patients
with AKI requiring CVVH and favours renal and patient
outcomes when compared to unfractionated heparin.
Material and methods
Study design
This was a multi-centre, randomized, non-blinded, pro-
spective clinical trial with parallel group design performed
in 10 ICUs in the Netherlands. The study was carried out
in accordance with the Declaration of Helsinki, and was
approved by the institutional review boards at each of the
participating study centres (see Acknowledgements).
The study was registered at clinicaltrials.gov number
NCT00209378. Informed consent was obtained from all
study participants or their next of kin. We use the acro-
nym CASH for citrate anticoagulation versus systemic
heparinisation.
Patients
Adults admitted to the ICUs of the participating centres,
and who required CVVH, were randomly assigned by
sealed opaque envelopes with concealed treatment allo-
cation inside, stratified by centre, and drawn by an inde-
pendent individual not involved in the trial, to receive
heparin or citrate for CVVH in predilution mode in a
single-blinded fashion. All randomized patients were
enroled. CVVH was started for AKI and uncontrolled
uraemia, diuretic-resistant volume overload, respiratory
distress, multiorgan failure, or any combination of these
features, at the discretion of the treating physician and
consulting nephrologist. Exclusion criteria were the pres-
ence of an increased bleeding risk (defined as a platelet
count below 40 × 109/L, an activated partial thrombo-
plastin time (aPTT) longer than 60 seconds, a pro-
thrombin time-international normalised ratio (PT-INR)
greater than 2.0 or recent major bleeding), age below 18
or over 80 years, the need for therapeutic systemic antic-
oagulation (heparin or coumarins) or a known HIT. The
administration of activated protein C or plasma ex-
change therapy were also considered exclusion criteria,
as was chronic dependence on renal replacement ther-
apy prior to admission to the ICU. The presence of liver
disease of any kind was not an exclusion criterion.
Study protocol
The participating centres used the locally available hae-
mofiltration machine, venous catheter and haemofilter.
In patients receiving heparin, commercially prepared
bicarbonate-buffered haemofiltration replacement solu-
tion (HF32bic, Dirinco, Rosmalen, the Netherlands) was
used in most patients; lactate-based (BH504, Dirinco)
haemofiltration replacement solution was used in six
patients. For citrate anticoagulation, we adapted the
protocol conceived by Pallson and Niles [6], and used a
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ment fluid (HFCitPre, Dirinco), acting as anticoagula-
tion and buffer in predilution mode, as described before
[17,18]. For composition of the replacement fluids used,
see Additional file 1. Patients anticoagulated with hep-
arin received a heparin bolus of 5,000 IU in a pre-filter
fashion at the arterial pole prior to the start of CVVH
and a separate heparin pump (20,000 IU/48 mL) was set
at 2.0 mL/h and adjusted targeting a systemic aPTT of
50 seconds. Patients anticoagulated with regional citrate
had a separate intravenous calcium drip, with calcium glu-
bionate (Calcium Sandoz, containing 0.225 mmol/mL cal-
cium, Novartis Consumer Health, Breda, The Netherlands).
Calcium administration was adapted to concentrations of
systemic ionised calcium by a specially designed algo-
rithm, targeting systemic ionised calcium levels of 1.0
to 1.35 mmol/L [19]; for calcium pump settings see
Additional file 1. Calcium levels in the extracorporeal
circuit were not measured routinely, in order to keep
the treatment protocol simple. Blood flow was initially set
at 180 mL/minute in both groups. Predilution replace-
ment flow rates varied between 2,000 and 4,000 mL/h
according to local guidelines. The rate of infusion of re-
placement solution was coupled to the blood flow, aiming
at stable citrate concentrations in the extracorporeal cir-
cuit. The replacement solution ran through a warming coil
set at 39°C.
The pH, anion gap, ionised and total calcium and their
ratio were monitored in patients on citrate, at least four
times daily. The first measurement was done 1 h after
initiation of CVVH. Routine daily laboratory measure-
ments included acid-base balance, electrolytes, haemo-
globin, and white blood cell and platelet counts. Also,
levels of magnesium and sodium were monitored to de-
tect citrate-related derangements. In patients on heparin
the aPTT was determined every 6 to 8 h. An electrocar-
diogram was made if hypocalcaemia (ionised calcium
below 0.9 mmol/L) occurred. Citrate accumulation was
suspected if the patient fulfilled one or more of the follow-
ing criteria: a ratio of total calcium to ionised calcium
greater than 2.5, clinical signs of hypocalcaemia (tetanic
symptoms or prolonged QT interval not due to medica-
tion), or progressive acidosis (pH <7.20) with an increased
anion gap (>13 mmol/L) in the presumed absence of an-
ions other than citrate. If there were signs of citrate accu-
mulation, CVVH was continued with heparin. Patients
treated with heparin, who were clinically suspected of hav-
ing developed a HIT, continued CVVH with citrate. Also,
in case of a clinically suspected bleeding episode, heparin
was discontinued and patients continued CVVH with re-
gional citrate anticoagulation. The crossover between
study arms was documented. Filters were routinely re-
placed after 72 hours of use, apart from incidental cases
when still functioning well (n = 2). CVVH was continuedat the discretion of the treating physician. Patients were
otherwise treated by board-certified intensivists, according
to international and national guidelines.
Study endpoints
Primary endpoints were patient mortality at 28 and 90 days
after initiation of CVVH and renal outcome. For renal
outcome, independence of renal replacement therapy
28 days after initiation of CVVH in surviving patients was
studied. Secondary endpoints were safety and efficacy.
Safety was defined as the absence of any adverse event ne-
cessitating discontinuation of study anticoagulant, such as
bleeding or HIT in the heparin group and citrate accumu-
lation in the citrate group. For efficacy, the survival time
of the first filter, the number of filters used and off-time
within the first 72 hours of therapy were studied. Add-
itionally, a cost analysis for the first 72 hours of prescribed
CVVH was performed. Follow up until day 90 was
achieved in 134 of the 139 (96%) patients.
Data collection
Severity of illness and organ failure were scored using
the acute physiology and chronic health evaluation II
(APACHE II) and the sequential organ failure assessment
(SOFA) on days 0 and 3. All data were prospectively col-
lected by the local researcher in the patient data manage-
ment system of the participating centre. A research nurse,
not involved in patient care, was responsible for the co-
ordination of the collection of case record forms and ac-
curacy of the database. The etiology of AKI, categorised as
ischaemic, due to sepsis or other (including contrast ne-
phropathy and rabdomyolysis), was assessed by the treat-
ing physician. The costs during the first 72 hours of
prescribed CVVH were calculated using the following pa-
rameters: cost of replacement solution used (during first
72 hours of therapy minus off-time), cost of heparin ad-
ministered in the heparin group, cost of calcium adminis-
tered in the citrate group, costs of total numbers of filter
sets used and the half-hourly wage of nursing staff per
filter change.
Statistical analysis
We hypothesized an absolute mortality reduction of 15%
after 28 days for patients on citrate, as compared to that
of patients on heparin, with an estimated mortality rate
of 65%. The power of the study was set to be 90% at 5%
significance, so that the sample size was targeted at 180
patients per group. Values are presented as the median
and range, because most data were non-normally distrib-
uted (Kolmogorov-Smirnov test, P <0.05). We compared
groups using the Mann-Whitney U-test, the chi square
(X2) test, or the Fisher exact test, where appropriate. Pa-
tient and filter survival data were analysed using Kaplan-
Meier plots and log rank testing. Data were analysed on
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protocol analysis, excluding patients who switched from
the assigned anticoagulation. Backward stepwise multiple
logistic regression was used to evaluate the contribution of
age, disease severity, prescribed dose and anticoagulation
regimen on mortality at 28 days. The Hosmer-Lemeshow
test was used to verify adequate calibration, as indicated
by a P-value >0.05. Additionally, univariate logistic regres-
sion was performed generating odds ratios for mortality at
28 days in the following subgroups: age (higher versus
lower than the median), APACHE II scores (higher versus
lower than the median), prescribed dose (higher or lower
than the recommended 20 mL/kg/h), sepsis versus non-
sepsis and circulatory or respiratory failure at ICU admis-
sion. A two-sided P-value <0.05 was considered statistically
significant; exact P-values are given unless <0.001.
Results
From April 2005 until March 2011, 139 patients were
randomly assigned to citrate or heparin. The AdditionalTable 1 Baseline characteristics
Citrate (n = 66)
Age, years 67 (36 to 87)
Male sex 44 (67)
Weight, kg 85 (50 to 180)
Reason for admission to ICU
Respiratory failure 23 (35)
Circulatory failure 18 (27)
Trauma 2 (3)
Post-CPR 4 (6)
Postoperative 19 (29)
Cause of acute kidney injury
Sepsis 27 (41)
Ischaemic 33 (50)
Other 6 (10)
At start of CVVH:
APACHE II 23 (11 to 53)
SOFA 10 (2 to 19)
SOFA, day 3 9 (2 to 20)
Mechanical ventilation 45 (81)
Vasopressor dependency 41 (75)
Length of stay in ICU, days 2 (0 to 30)
Creatinine, μmol/L 326 (54 to 704)
Urea, mmol/L 20.1 (3.3 to 54)
Potassium, mmol/L 4.6 (2.4 to 8.8)
Diuresis in 24 h prior to CVVH, mL 360 (0 to 3,975)
Prescribed dose, mL/kg/h 21 (8 to 32)
Median (range) or number (percentage) where appropriate. CVVH, continuous veno
physiology and chronic health evaluation score; SOFA, sequential organ failure assefiles present number of patients included by the participat-
ing centres (see Additional file 2) and a consort diagram
(see Additional file 3). Baseline and CVVH characteristics
were similar between groups, apart from more frequent
respiratory failure on admission in the heparin group
(Table 1). In the citrate group, 26 of the 66 patients (39%)
had sepsis versus 26 of the 73 patients (36%) in the hep-
arin group (P = 0.73). An aPTT >50 sec was achieved in
136/247 measured time points (55%) for the first filter in
the heparin group. The study was prematurely discontin-
ued because of slow enrolment of patients.
Primary outcome measures
Mortality rates at 28 and 90 days did not differ between
groups: 22/66 citrate patients (33%) died versus 25/72
patients (35%) in the heparin group at 28 days, and 27/
65 citrate patients (42%) died versus 29/69 patients
(42%) in the heparin group at 90 days (P = 1.00 for
both). Indeed, survival curves for 28- and 90-day out-
comes were similar among anticoagulation groupsHeparin (n = 73) P-value
67 (23 to 85) 0.51
49 (67) 1.00
80 (40 to 220) 0.54
0.02
45 (62)
10 (14)
2 (3)
1 (1)
15 (21)
0.64
27 (37)
37 (51)
9 (13)
25 (6 to 43) 0.10
11 (3 to 18) 0.45
9 (1 to 16) 0.82
55 (81) 1.00
54 (79) 0.53
2 (0 to 25) 0.37
325 (56 to 845) 0.66
23.6 (4 to 64) 0.38
4.6 (2.9 to 6.5) 0.83
421 (0 to 2745) 0.65
23 (7 to 35) 0.18
venous haemofiltration; CPR, cardiopulmonary resuscitation; APACHE-II, acute
ssment.
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any difference in mortality at 28 and 90 days: 18/61 cit-
rate patients (30%) died versus 15/48 patients (31%) in
the heparin group at 28 days and 23/60 citrate patients
(38%) died versus 18/47 patients (38%) in the heparin
group at 90 days (P = 1.00 for both). Multiple logistic
regression showed higher age and high APACHE II
scores at admission to be independent predictors of
mortality at 28 days (P = 0.05 for both), whereas pre-
scribed dose and anticoagulation regimen were not. In
univariate logistic regression, there was no benefit
from citrate anticoagulation in terms of mortality re-
duction at 28 days in any of the defined subgroups (see
Additional file 4). Concerning renal outcome, there
was no difference between the groups in dialysis inde-
pendence among surviving patients 28 days after start
of CVVH, with 29/43 patients (67%) in the citrate
group versus 33/47 patients (70%) in the heparin group
(P = 0.82).Figure 1 Patient survival. (a) Survival 28 days after initiation of
continuous venovenous haemofiltration (CVVH). (b) Survival 90 days
after initiation of CVVH. Continuous line represents citrate, dotted
line represents heparin.Secondary outcome measures
Adverse events necessitating discontinuation of the pri-
mary assigned anticoagulant occurred with heparin more
frequently than with citrate (Table 2 and Additional file 3).
In one patient, citrate was discontinued and anticoagula-
tion withheld. Citrate accumulation was suspected in 5 of
the 66 patients (8%) randomized to citrate and proven in 4
patients (6%); in 2 patients there was a persistently ele-
vated anion gap, attributed to citrate accumulation, and in
2 patients the calcium ratio exceeded 2.5 after 60 and
72 hours of therapy. Finally, one patient was erroneously
ascribed to citrate accumulation. Of all measured ionised
calcium levels within 72 hours in the citrate group, 61/508
(12%) were <0.9 mmol/L and none of the measurements
exceeded 1.35 mmol/L. Potential treatment related de-
rangements, such as metabolic alkalosis, hypernatremia or
hypomagnesemia did not occur more often in the citrate
group than in the heparin group (Table 2). Clinically sus-
pected HIT was reported in 6 of 73 patients (8%) on hep-
arin. There was a trend for fewer bleeding episodes in the
citrate group (n = 5 versus n = 10 in the heparin group,
P = 0.08), however, this did not result in a difference be-
tween groups in patients needing >2 erythrocyte concen-
trates (2 versus 4 patients in the heparin group, P = 0.68).
Efficacy parameters suggested superiority for citrate
(Table 2). Survival times of the first filter were superior
for citrate, with survival curves shown in Figure 2. An
analysis excluding patients in whom the filter ran for more
than 72 hours did not differ from the presented results.
Furthermore, the off-time within 72 hours was less with
citrate (1 (0 to 12) h versus 3 (0 to 31) h for heparin, P =
0.002), as were the number of filters used (1 (1 to 5) versus
2 (1 to 9) for heparin, P = 0.002). In per-protocol analysis
the total duration of CVVH was longer in the citrate
group, at 117 hours versus 70 hours for heparin (P = 0.04).
There was a higher incidence of circuit disconnection due
to clotting of the circuit in the heparin group (51% ver-
sus 24% in the citrate group) and more elective filter
changes in the citrate group (30% versus 9% in the hep-
arin group, P = 0.01). The total costs during the first
72 hours of prescribed CVVH were lower in citrate-
based CVVH (P <0.001, Table 2.)
Discussion
The present multi-centre randomized controlled trial in
critically ill patients with AKI suggests that regional antic-
oagulation with citrate for CVVH is superior to heparin in
terms of safety, efficacy, and costs, but not in terms of
renal and patient outcomes. Mortality rates 28 and 90 days
after initiation of CVVH did not differ between the two
anticoagulation regimens.
Independency of dialysis at day 28 was achieved in about
70% of surviving patients either anticoagulated with citrate
or with heparin. These numbers are low compared to
Table 2 Secondary outcomes
Citrate (n = 66) Heparin (n = 73) P-value
Safety, discontinuation of study anticoagulant
Within 72 h 2 (3) 9 (12) 0.06
Bleeding episode 0 2 (22)
HIT 0 2 (22)
Frequent filter failure 0 3 (33)
Citrate accumulation 2 (100) 0
Miscellaneous 0 2 (22)
Within 28 days 5 (8) 24 (33) <0.001
Bleeding episode 0 8 (33)
HIT 0 6 (25)
Frequent filter failure 0 7 (29)
Citrate accumulation 4 (80) 0
Miscellaneous 1 (20) 3 (13)
Bleeding episode within 28 days 3 (5) 10 (14) 0.08
Requirement of >2 packed cells 2 (3) 4 (6) 0.68
Metabolic derangements, during first 72 hours of therapy
pH >7.50 1 (2) 0 1.00
Sodium >150 mmol/L 4 (7) 3 (5) 0.71
Magnesium <0.7 mmol/L 8 (15) 6 (9) 0.40
Efficacy, intention to treat
Survival time first filter, h 46 (1 to 138) 32 (1 to 72) 0.02
Number of filters used within 72 h 1 (1 to 5) 2 (1 to 9) 0.002
Off-time within 72 h, h 1 (0 to 12) 3 (0 to 31) 0.002
Reason for circuit disconnection 0.01
Circuit clotting 16 (24) 35 (51)
Elective filter change (72 h) 20 (30) 6 (9)
Catheter dysfunction 4 (6) 8 (12)
Termination of CVVH1 10 (15) 10 (12)
Transport 4 (6) 1 (1)
Technical problems 8 (12) 5 (7)
Therapy change2 2 (3) 3 (4)
Miscellaneous 2 (3) 1 (1)
Total duration of CVVH, h 123 (4 to 999) 73 (5 to 672) 0.18
Efficacy, per protocol n = 61 n = 49
Number of filters used within 72 h 1 (1 to 5) 2 (1 to 9) 0.04
Off-time within 72 h, h 2 (0 to 12 ) 0 (0 to 31) 0.01
Total duration of CVVH, h 117 (4 to 999) 70 (5 to 672) 0.04
Costs
Total cost of first 72 h of CVVH, € 553 (436 to 872) 663 (320 to 1,319) <0.001
Replacement fluid, € 316 (225 to 366) 429 (119 to 736) <0.001
Wage nursing staff for filter change, € 19 (19 to 95) 38 (19 to 171) 0.02
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Table 2 Secondary outcomes (Continued)
Filter sets, € 85 (85 to 425) 170 (85 to 765) 0.02
Heparin, € 0 6.46 (3.84 to 6.74) <0.001
Calcium glubionate, € 82 (70 to 84) 0 <0.001
Median (range) or number (percentage), where appropriate. HIT, heparin-induced thrombocytopenia; CVVH, continuous venovenous haemofiltration; € = euro.
1Treatment withdrawal or renal function recovery.
2Continuous renal replacement therapy to intermittent renal replacement therapy.
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described by others [21]. We evaluated renal function re-
covery at 28 days after start of CVVH, while later recovery
is still possible. Also, in our study there was less AKI due
to sepsis and more due to ischaemic events in comparison
to the trial reported by Oudemans et al. [14], and an is-
chaemic aetiology may carry a worse renal prognosis.
We powered the study for approximately 360 patients
on the basis of 28-day mortality; however enrolment was
slower than anticipated, mostly due to the need for
therapeutic systemic anticoagulation or the development
of increased bleeding risk. This resulted in premature
discontinuation of the study after 6 years of enrolment.
The most substantial difference in mortality observed
was 2% in favour of citrate at 28 days. In hindsight, this
difference to become statistically significant at the 5%
level would have necessitated 9,600 patients per group
for 90% power. Also, in the initial power analysis we
used an estimated mortality rate of 65% at 28 days in the
heparin group, but the observed mortality rate was sub-
stantially lower. This tendency for improving AKI out-
comes over the years has been noted by others [22].
To our knowledge, this is the second randomized clinical
trial comparing vital outcome in citrate and heparin-based
CVVH in predilutional mode, using citrate-containing re-
placement fluid [15]. Most trials comparing heparin to cit-
rate in CVVH had small numbers of patients and mainly
focused on filter survival [10-13], and only two had mortal-
ity as an outcome measure [14,15]. Our findings are inFigure 2 Survival times for the first filter. Continuous line
represents citrate, dotted line represents heparin.concordance with a recent trial comparing systemic
heparin to regional citrate [15], where 28-day mortality
was similar for both groups (47% mortality for citrate,
41% for heparin at 28 days). However, our results are
in contrast with a trial comparing the low molecular
weight heparin nadroparin to systemically adminis-
tered citrate in a post-dilution fashion [14], where cit-
rate reduced mortality (90-day mortality 45% for
citrate, 62% for nadroparin). Mortality rates in the
present study were somewhat lower than in previous
studies and this could, at least in part, be attributed to a
lower frequency of sepsis in our patient group. Also,
APACHE-II scores at baseline, and age, were higher as re-
ported by Oudemans et al. [14], yet similar to those re-
ported by Hetzel et al. [15]. We could not confirm the
beneficial effect on mortality rates in cases of sepsis that
were suggested by Oudemans et al.; survival rates were
similar for septic and non-septic patients and the anticoa-
gulation used did not affect this number. Moreover, the
lack of benefit for citrate regarding mortality persisted in
subgroup analyses.
Citrate was safer than heparin in terms of less need for
discontinuation of the anticoagulant. Citrate accumulation
was present in 6% of patients. The frequency of accumula-
tion in our study is similar to rates reported by others
[17,18]. The incidence of clinically suspected HIT (6/73
patients (8%) in the heparin group) was similar to num-
bers reported by Hetzel et al., yet higher than numbers re-
ported by others [23,24]. When HIT was suspected, the
diagnosis was not routinely confirmed by antibody testing,
so that the incidence may have been overestimated.
Citrate was superior to heparin in terms of efficacy.
The filter survival time of the first filter used was super-
ior for citrate compared to heparin, supporting the bene-
ficial effect of citrate in this respect as described by
others [15-17]. Improved filter survival implicates less
off-time, which indeed was the case in our study for cit-
rate. An aPTT >50 seconds, which we used as indication
of adequate anticoagulation during heparin treatment,
was achieved in 55% of the measurements of the first fil-
ter. This could partly explain the difference in filter sur-
vival, even though some have questioned whether aPTT
is a determinant of filter survival [25,26]. Besides, hep-
arin was administered in a pre-filter fashion, therefore
systemically measured aPTTs could underestimate actual
aPTT in the extracorporeal circuit [25]. Also, there seems
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ture, where some target a lower aPTT of 40 to 45 seconds
[25]. This study demonstrates clinical practice, where antic-
oagulation using heparin is challenging due to problems
such as heparin resistance and an increased bleeding risk
when administering high doses of heparin, especially in crit-
ically ill patients [27-29]. Nevertheless, the survival times of
the first filter in the heparin group were similar to those de-
scribed by others [10-13,15]. Additionally, the costs of the
first 72 hours of prescribed CVVH were lower in citrate-
based CVVH, which can be attributed to lower costs of fil-
ter sets and less labour due to fewer filters used during
treatment with citrate, adding another argument in favour
of citrate as compared to heparin.
Limitations of the present study include the long in-
clusion period, because enrolment was slower than an-
ticipated. Subsequently, the study was prematurely
discontinued and therefore underpowered for mortal-
ity. We cannot exclude that the availability of citrate-
based CVVH and positive experiences concerning
filter survival by physicians and nursing staff raised the
threshold for enrolling patients in the study and thus
resulted in selection bias. An envelope-derived method
for randomization may be inferior to a computer-based
method. There was a substantial range in the pre-
scribed dose and in some patients recommended doses
exceeding 20 mL/kg/h were not achieved. However,
there was no difference in the prescribed dose between
groups nor did the prescribed dose contribute to mor-
tality. There was a slight imbalance between groups in
reasons for admission to the ICU, but there were no
differences regarding anticoagulation and mortality be-
tween admission categories. Though a beneficial effect
of one biocompatible filter over the other has not been
demonstrated, we cannot rule out that some bias is in-
troduced, as the centres utilized different filters.
The total duration of CVVH was longer in the citrate
group in a per protocol analysis. We hypothesize that this
is due to longer filter survival with citrate, since it is com-
mon practice to postpone termination of CVVH until cir-
cuit failure is impending. Although citrate and heparin
treatment carried similar mortality rates during CVVH,
the improved filter survival, less need for discontinuation
of the anticoagulant due to adverse events and lower costs
are substantial advantages of citrate and should be consid-
ered when deciding on which anticoagulation in CVVH is
best for critically ill patients with AKI. Our results support
current guidelines on anticoagulation in CVVH, suggest-
ing citrate rather than heparin for anticoagulation in pa-
tients without contraindications for citrate [30].
Conclusions
In conclusion, renal outcome and patient mortality were
similar for citrate- and heparin-based anticoagulationduring CVVH in the critically ill patient with AKI, in this
randomized multi-centre clinical trial. However, citrate
had advantages in terms of safety, efficacy and costs and
should therefore be considered as first choice for anticoa-
gulation in CVVH.
Key messages
 Patient mortality and renal outcome were similar for
citrate and heparin anticoagulation during CVVH in
the critically ill patient with AKI
 Citrate was safer than heparin in terms of less need
for discontinuation of the anticoagulant due to
adverse events during CVVH
 Citrate was superior to heparin in terms of efficacy
demonstrated by improved filter survival and less
off-time during CVVH
 The costs of the first 72 hours of prescribed CVVH
were lower in citrate-based CVVH as compared to
heparin-based CVVH.
Additional files
Additional file 1: Composition of replacement fluids and calcium
pump settings. Composition of the replacement fluids used, the rate
of infusion of replacement solution coupled to the blood flow and the
protocol for calcium pump adjustments during citrate-based continuous
venovenous haemofiltration (CVVH).
Additional file 2: List of participating centres and number of patients
included. The number of patients included by participating centres.
Additional file 3: Consort diagram. Consort diagram demonstrating
eligible patients. Also, crossovers between anticoagulation groups are listed.
Additional file 4: Mortality in subgroups at 28 days. Mortality at
28 days for citrate and heparin in the following subgroups: age (higher
versus lower than median), acute physiology and chronic health
evaluation (APACHE) II scores (higher versus lower than the median),
prescribed dose (higher or lower than the recommended 20 mL/kg/h),
sepsis versus non-sepsis and circulatory or respiratory failure at
ICU admission.
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